Alzheimer’s Progression Slowed by Drug in Major Trial https://apple.news/Ak4Xc5nA5ThyiEY6_S-bP4w
Eisai Co. and partner Biogen Inc. said their Alzheimer’s drug lecanemab slowed the disease, becoming the first medicine to clearly blunt the progression of the most common type of dementia in a final-phase trial.
The drug slowed cognitive decline in people with early Alzheimer’s by 27% over 18 months when compared with a placebo using a common rating scale, meeting the main goal of the trial, according to a statement from the companies on Tuesday. While modest in size, the effect was highly statistically significant. ..